Collaborative Arrangement, Net Income

No definition available.

Name:	amgn_CollaborativeArrangementNetIncome
Namespace Prefix:	amgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative Arrangement, Research and Development Expense, Net

+ References

No definition available.

+ Details

Name:	amgn_CollaborativeArrangementResearchandDevelopmentExpenseNet
Namespace Prefix:	amgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Royalty Percentage

+ References

No definition available.

+ Details

Name:	amgn_CollaborativeArrangementRoyaltyPercentage
Namespace Prefix:	amgn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of Countries Product is Marketed and Sold

+ References

No definition available.

+ Details

Name:	amgn_NumberofCountriesProductsisMarketedandSold
Namespace Prefix:	amgn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of Net Profits After Deducting Certain Partner Related Costs

+ References

No definition available.

+ Details

Name:	amgn_PercentageofNetProfitsAfterDeductingCertainPartnerRelatedCosts
Namespace Prefix:	amgn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of Related Development Costs

+ References

No definition available.

+ Details

Name:	amgn_PercentageofRelatedDevelopmentCosts
Namespace Prefix:	amgn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_RecoveryOfDirectCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=amgn_CollaborativeArrangementswithAstrazenecaPlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=amgn_CollaborativeArrangementswithBayerHealthCarePharmaceuticalsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=amgn_NexavarMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=amgn_OtherRevenuesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative arrangements (Details) $ in Millions	3 Months Ended		6 Months Ended
Collaborative arrangements (Details) $ in Millions	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2015 USD ($) country	Jun. 30, 2014 USD ($)
Astrazeneca Plc. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percentage of related development costs for the 2012-2014 period that were funded by partner			65.00%
Astrazeneca Plc. [Member] \| Research and Development Expense [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Cost recoveries	$ 3	$ 39	$ 23	$ 49
Bayer HealthCare Pharmaceuticals Inc. [Member] \| Nexavar [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of countries product is marketed and sold \| country			100
Collaboration, royalty percentage in the high 30s			30.00%
Percentage of net profits after deducting certain partner related costs			50.00%
Collaboration, net R&D expenses	7	10	$ 12	21
Bayer HealthCare Pharmaceuticals Inc. [Member] \| Nexavar [Member] \| Other revenues [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration profit	$ 84	$ 87	$ 156	$ 165